There is increasing recognition of the importance of assessing patient-reported symptoms as part of clinical care. Recent randomized trials of clinic-based symptom monitoring have found that it is associated with reduced symptom severity, better quality of life, and reduced hospitalization and emergency room visits. Our clinic established use of a modified Edmonton Symptom Assessment Scale (ESAS) in August 2015. All patients presenting for radiation oncology (RO) services complete the form at each clinic visit. As these patients often experience multiple symptoms that affect quality of life and outcomes, recent symptom management literature focuses on identifying symptom clusters.
Despite advancements in screening, diagnosis, and treatment, cancer remains the second leading cause of death in the US since 1938, surpassed only by heart disease. Lifestyle medicine (LM) is positioned to influence not only cancer incidence but also the quality of life for cancer survivors and their overall health outcomes, both cancer-specific and general. Guidelines applicable to both primary and tertiary prevention will be reviewed, emphasizing the importance of LM pillars to include maintaining a healthy body weight, following a plant-predominant nutrition plan, limiting red meat and avoiding processed meat, restricting sugar-sweetened drinks, engaging in sufficient physical activity, and avoiding alcohol consumption and tobacco use. The recommendation to engage in aerobic and resistance exercise with curative intent to mitigate side effects associated with cancer therapy will be discussed. Experiential approaches to care delivery will be presented to facilitate effective implementation. Case studies will be presented focusing on premenopausal and postmenopausal breast cancer. <!----> <!----> <!----> <!---->
1 October 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
39 Background: Health-related quality of life (HRQoL) outcomes are important in treatment selection for prostate cancer. The Expanded Prostate Cancer Index Composite (EPIC) is a validated and widely-utilized HRQoL survey which accounts for newer radiotherapeutic, surgical, and hormonal treatment methods. We present a meta-analysis of patient reported HRQoL outcomes collected with EPIC and compare HRQoL trends with radiation therapy, surgery, or active surveillance as primary treatment. Methods: The PubMed database was systematically searched for all studies which presented data directly derived from the use of EPIC on patients with prostate cancer prior to 07/09/2014. All eligible studies were selected for either inclusion and analysis or exclusion based on pre-determined criteria. The data from included studies was compiled and a simulation-based estimation method using Approximate Bayesian Computation was performed to obtain missing standard deviation estimate. A longitudinal meta-analysis was conducted to estimate EPIC-profiles for each component using Bayesian p-spline method. Results: Over 4,000 studies were searched, 152 were deemed eligible, and 39 were included. The calculated mean summary score estimates are shown in the attached table. Conclusions: In the urinary domain, radical prostatectomy (RP) has lower acute scores than active surveillance (AS) or radiation therapy (RT) without long-term difference. In the bowel domain, RT has lower scores than AS or RP acutely and long-term. In the sexual domain, RT and RP have lower acute scores than AS. RP has lower scores than RT without long-term difference. In the hormonal domain, little difference was noted between modalities. [Table: see text]